Aurion Biotech
Aurion Biotech develops regenerative cell therapies for the treatment of blindness and vision loss, with a lead program focused on corneal endothelial cell therapy for patients with corneal endothelial disease. Its therapies aim to restore vision by replacing lost or dysfunctional endothelial cells using human donor cells, providing a less invasive alternative to traditional corneal transplantation. The organization’s mission is to expand global access to advanced ophthalmic care and address significant unmet needs in treating blindness.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology
- Founded
- 2022
- Employees
- 116
- Stage
- Clinical stage
- Members see funding amounts. .
Is this your organization? Claim it
Jacob Colker reflects on Hubble Network raised $200M at a $1.6B valuation in LinkedIn roundup of Seattle wins
A LinkedIn article by Jacob Colker (published Sep 29, 2026) highlights recent Seattle achievements, including Hubble Network raising $200 million at a $1.6 billion valuation to connect ordinary Bluetooth devices. The piece frames these stories as reminders that the Seattle region is more influential than commonly perceived.
Gennev Founder Jill Angelo Steps Down After Acquisition; Aurion Biotech CEO Replaced Following Alcon Majority Stake; Temporal Adds New Leadership
Jill Angelo, founder and CEO of menopause startup Gennev, stepped down following its acquisition by Unified Women’s Healthcare, while Aurion Biotech replaced CEO Greg Kunst with Arnaud Lacoste after Alcon acquired a majority stake. Temporal also announced leadership additions with Jim Cyb as president and Sahir Azam as an independent board member.
GeekWire 200 Q1 2025: Highspot Leads as Helion Rises to No. 2 After $425M Funding; Truveta, Statsig, Protect AI Also Advance
The GeekWire 200 Q1 2025 update highlights rapidly growing Pacific Northwest tech startups, with Highspot retaining No. 1 and Helion rising to No. 2 after a $425 million funding round. Other notable movers include Truveta, Statsig, Protect AI, Carbon Robotics, and Stoke Space, reflecting dynamic shifts in the regional tech landscape.
People
-
Arnaud Lacoste Executive, Executive Officer, CEO and Chief Scientific Officer
-
Greg Kunst Executive, Executive Officer, Director, CEO
Online
Questions about Aurion Biotech
What is Aurion Biotech?
Aurion Biotech is a startup that develops regenerative cell therapies to treat blindness and vision loss, with a lead program focused on corneal endothelial disease. Aurion Biotech is based in Seattle.
What has Aurion Biotech been in the news for?
GeekWire reported in April 2025 that Aurion Biotech’s CEO was replaced.
Who are the people behind Aurion Biotech?
Arnaud Lacoste is listed as CEO and chief scientific officer at Aurion Biotech. Greg Kunst is listed as CEO and director at Aurion Biotech.
Who invested in Aurion Biotech, and how much has it raised?
Members of Seattle Flow see Aurion Biotech's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Aurion Biotech based?
Aurion Biotech is based in Seattle.
When was Aurion Biotech founded?
Aurion Biotech was founded in 2022.